Major Brands Are Investing in Generative AI for Digital Commerce. They Need to Prioritize Data Transparency to Build Consumer Trust.

 

 

In the rapidly evolving world of digital commerce, how can businesses harness the power of generative AI without crossing the ethical line of consumer privacy? Making best use of generative AI in digital commerce is proving a more difficult balancing act than the initial hype around tools like ChatGPT may have signaled.

A recent study by the Retail AI Council and Salesforce, involving over 1,300 global retailers, highlighted that there’s both enthusiasm for and major hurdles in front of adopting generative AI for digital commerce applications within the retail sector. Despite facing significant data management challenges—such as accessibility, integration, bias, hallucinations, and toxicity—a strong majority (81%) of retailers maintain a dedicated AI budget, with generative AI poised to significantly impact sales, margins, and operational efficiencies by 2029. Even with that, though, only 30% of these retailers are implementing generative AI strategies to enhance customer and employee experiences, and reflecting persisting consumer privacy concerns in the industry, only 17% are achieving a comprehensive customer view.

Jon Reily, a top omnichannel retail expert and strategist, and the Senior Vice President of Commerce and Loyalty at Bounteous, weighed in on this crucial debate of the best practices for deploying generative AI for digital commerce applications, highlighting the fine balance between personalization and privacy.

“This level of personalization is fantastic for brands, it’s like having a crystal ball that predicts market trends, but at an ethical standpoint, it’s like walking a tightrope over a privacy pit and one that nobody wants to fall into,” Reily said.

Article written by Daniel Litwin.

 

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More